Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin in the Prevention of Nausea and Vomiting Induced by Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First course of chemotherapy ( cisplatin or doxorubicin at a dose of at least 50mg per square meter)~* Written informed consent must be obtained before initiating the protocol procedures~Exclusion Criteria:~* ECOG 3~* Nausea and vomiting within the past 1 day~* Gastrointestinal obstruction~* Concurrent use of opioid~* Patients with brain metastases~* History of allergic or other adverse reaction to gabapentin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): Placebo:~* Five and four days before chemotherapy (day -5 and day -4): 1x daily~* Three and two days before chemotherapy (day -3 and day -2): 2x daily~* One day before to five days after chemotherapy ( day -1 to day 5): 3x daily
- Gabapentin (Type: EXPERIMENTAL): Gabapentin 300mg:~* Five and four days before chemotherapy (day -5 and day -4): 1x daily~* Three and two days before chemotherapy (day -3 and day -2): 2x daily~* One day before to five days after chemotherapy ( day -1 to day 5): 3x daily

Based on this trial design, predict the completion outcome and termination type (if applicable).